Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity

Summary

Zealand Pharma announced the initiation of the ZUPREME Phase 3 registrational program evaluating petrelintide in patients with overweight or obesity. This represents progression to late-stage clinical development for the investigational obesity treatment.